have been shown to reduce the frequency of attacks. The disadvantages to these are side effects, expense, and inconvenient route of administration. With newer subcutaneous (SC) C1 esterase inhibitor (C1-INH) replacement, easier administration and superior efficacy are anticipated. We assessed historical attack frequency in our cohort of patients before and after starting SC C1-INH. METHODS: This study was IRB exempt. We retrospectively assessed attack frequency per history while patients were on prophylaxis with IV C1-INH or without prophylaxis. This was compared to attack frequency after these patients were switched to SC C1-INH. Dosing was 1000-2000 U twice weekly and 3000-9000 U twice weekly for IV and SC therapy, respectively. RESULTS: Of 19 patients on SC C1-INH, we had sufficient data on 9 females and 3 males to make an adequate comparison. The average age of our subjects was 47.5 years. Attack frequency before starting the SC therapy was 38.7 attacks/year on average (range: 12 to 120 attacks/year). Attack frequency after starting SC therapy was reduced to 3.8 attacks/year on average (range: 0 to 12 attacks/year). Overall, the patients tolerated the SC injections well without any significant side effects and were satisfied with the route of administration. CONCLUSIONS: Subcutaneous prophylactic therapies are likely to lead to great improvement in the care of HAE patients who are anticipated to have an improved quality of life with fewer attacks and ease of medication administration.
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Exploring To obtain perspectives from patients with HAE, we conducted interviews to explore attributes of C1-INH(SC) replacement that may contribute to better HRQoL. METHODS: Ten adult HAE patients (> _18) using C1-INH(SC) replacement therapy for at least three months were recruited from four US sites. Trained interviewers conducted 60-minute telephone interviews following a semi-structured interview guide. Interviews were audio-recorded, transcribed, and anonymized. Transcripts were analyzed using thematic analysis based on grounded theory principles. RESULTS: C1-INH(SC) impacted patients' HRQoL differently depending on whether they were on effective intravenous HAE prophylaxis prior to C1-INH(SC). Patients previously on intravenous HAE prophylaxis found the subcutaneous delivery of C1-INH(SC) to be convenient and easy to self-administer compared to intravenous medications requiring assistance from a health professional/family member. This enabled patients to travel freely and feel more independent. Patients not on effective HAE prophylaxis previously experienced these benefits and less anxiety and depression due to the uncertainty of when/where a debilitating HAE attack might occur. Productivity at work and participation in social and physical activities also increased. CONCLUSIONS: C1-INH(SC) gave patients a feeling of control over their disease, rather than feeling the helplessness associated with poorlycontrolled HAE. These interviews provide insights into the advantages of C1-INH(SC) replacement and the HRQoL-related benefits of effective HAE prophylaxis.
